Repair of and checkpoint response to topoisomerase I-mediated DNA damage

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 532, Issue 1-2, 2003, Pages 173-203

  Pommier, Yves ^a   Redon, Christophe ^a   Rao, V Ashutosh ^a   Seiler, Jennifer A ^a   Sordet, Olivier ^a   Takemura, Haruyuki ^a   Antony, Smitha ^a   Meng, LingHua ^a   Liao, ZhiYong ^a   Kohlhagen, Glenda ^a   Zhang, HongLiang ^a   Kohn, Kurt W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ATM; ATR; BRCA1; BRCA2; Camptothecin; Cell cycle checkpoints; Homologous recombination; Mre11; RAD51; RAD52; RPA, DNA PK; Tdp1; Topoisomerase

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CARBAZOLE DERIVATIVE; CYTARABINE; DACTINOMYCIN; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; GEMCITABINE; ISOQUINOLINE DERIVATIVE; PHENANTHRIDINE DERIVATIVE; TRABECTEDIN;

BIOACCUMULATION; CELL CYCLE; CELL KILLING; CHROMATIN; DISEASE COURSE; DNA CLEAVAGE; DNA DAMAGE; DNA MODIFICATION; DNA REPAIR; DNA REPLICATION; DNA SUPERCOILING; DRUG SELECTIVITY; GENETIC DISORDER; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSESTERIFICATION; TUMOR GROWTH; YEAST CELL;

EID: 10744233671     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2003.08.016     Document Type: Review

References (286)

1. Zhang H., Barceló J.M., Lee B., Kohlhagen G., Zimonjic D.B., Popescu N.C., Pommier Y. Human mitochondrial topoisomerase I. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10608-10613.
2. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70:2001;369-413.
3. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell. Biol. 3:2002;430-440.
4. Lee M.P., Brown S.D., Hsieh T.-S. DNA topoisomerase I is essential in Drosophila melanogaster. Proc. Natl. Acad. Sci. U.S.A. 90:1993;6656-6660.
5. Morham S., Kluckman K.D., Voulomanos N., Smithies O. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol. Cell. Biol. 16:1996;6804-6809.
6. Thrash C., Voelkel K., DiNardo S., Sternglanz R. Identification of Saccharomyces cerevisiae mutants deficient in DNA topoisomerase I activity. J. Biol. Chem. 259:1984;1375-1377.
7. Uemura T., Morikawa K., Yanagida M. The nucleotide sequence of the fission yeast DNA topoisomerase II gene: structural and functional relationships to other DNA topoisomerases. EMBO J. 5:1986;2355-2361.
8. Krogh B.O., Shuman S. A poxvirus-like type IB topoisomerase family in bacteria. Proc. Natl. Acad. Sci. U.S.A. 99:2002;1853-1858.
9. Zhu J., Schiestl R.H. Topoisomerase I involvement in illegitimate recombination in Saccharomyces cerevisiae. Mol. Cell. Biol. 16:1996;1805-1812.
10. Kohn K.W. DNA filter elution: a window on DNA damage in mammalian cells. Bioessays. 18:1996;505-513.
11. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:1989;351-375.
12. Hooper D.C. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 31(Suppl. 2):2000;S24-S28.
13. Pourquier P., Pommier Y. Topoisomerase I-mediated DNA damage. Adv. Cancer Res. 80:2001;189-216.
14. Pommier Y., Kohlhagen G., Laco G.S., Kroth H., Sayer J.M., Jerina D.M. Different effects on human topoisomerase I by minor groove and intercalated deoxyguanosine adducts derived from two polycyclic aromatic hydrocarbon diol epoxides at or near a normal cleavage site. J. Biol. Chem. 277:2002;13666-13672.
15. Pourquier P., Gioffre C., Kohlhagen G., Urasaki Y., Goldwasser F., Hertel L.W., Yu S., Pon R.T., Gmeiner W.H., Pommier Y. Gemcitabine (2′,2′-difluoro-2′-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin. Cancer Res. 8:2002;2499-2504.
16. Gupta M., Fujimori A., Pommier Y. Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta. 1262:1995;1-14.
17. Pommier Y., Pourquier P., Fan Y., Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta. 1400:1998;83-105.
18. Pommier Y., Pourquier P., Urasaki Y., Wu J., Laco G. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist. Update. 2:1999;307-318.
19. Meng L.-H., Liao Z.-H., Pommier Y. Non-camptothecin DNA topoisomerase I inhibitors in cancer chemotherapy. Curr. Top. Med. Chem. 3:2003;305-320.
20. Y. Pommier, J.M. Barceló, T. Furuta, H. Takemura, O. Sordet, Z.-H. Liao, K.W. Kohn, Topoisomerase I Inhibitors: Molecular and Cellular Determinants of Activity, http://www.discover.nci.nih.gov/pommier/topo1.htm.
21. Pourquier P., Ueng L.-M., Fertala J., Wang D., Park H.-J., Essigman J.M., Bjornsti M.-A., Pommier Y. Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. J. Biol. Chem. 274:1999;8516-8523.
22. Lesher D.T., Pommier Y., Stewart L., Redinbo M.R. 8-Oxoguanine rearranges the active site of human topoisomerase I. Proc. Natl. Acad. Sci. U.S.A. 99:2002;12102-12107.
23. S Antony, PB Arimondo, Y Pommier, Position-specific enhancement of top1 cleavage complexes by triple helix forming oligonucleotides, Nucl. Acids Res., in press.
24. Horwitz S.B., Chang C.K., Grollman A.P. Studies on camptothecin. I. Effects of nucleic acid and protein synthesis. Mol. Pharmacol. 7:1971;632-644.
25. Holm C., Covey J.M., Kerrigan D., Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 49:1989;6365-6368.
26. O′Connor P.M., Nieves-Neira W., Kerrigan D., Bertrand R., Goldman J., Kohn K.W., Pommier Y. S-Phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun. 3:1991;233-240.
27. Pourquier P., Pilon A., Kohlhagen G., Mazumder A., Sharma A., Pommier Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps: importance of DNA end phosphorylation and camptothecin effects. J. Biol. Chem. 272:1997;26441-26447.
28. Mattern M.R., Hofmann G.A., McCabe F.L., Johnson R.K. Synergic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 10864). Cancer Res. 51:1991;5813-5816.
29. Wu J., Liu L.F. Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucl. Acids Res. 25:1997;4181-4186.
30. Hsiang Y.-H., Lihou M.G., Liu L.F. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:1989;5077-5082.
31. Goldwasser F., Shimizu T., Jackman J., Hoki Y., O'Connor P.M., Kohn K.W., Pommier Y. Correlations between S- and G2-phase arrest and cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 56:1996;4430-4437.
32. Nitiss J.L., Wang J.C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol. Pharmacol. 50:1996;1095-1102.
33. Morris E.J., Geller H.M. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J. Cell. Biol. 134:1996;757-770.
34. Borovitskaya A.E., D'Arpa P. Replication-dependent and independent camptothecin cytotoxicity of seven human colon tumor cell lines. Oncol. Res. 10:1998;271-276.
35. Daoud S.S., Munson P.J., Reinhold W., Young L., Prabhu V., Yu Q., LaRose J., Kohn K.W., Weinstein J.N., Pommier Y. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res. 63:2003;2782-2793.
36. Zhou Y., Gwadry F.G., Reinhold W.C., Miller L.D., Smith L.H., Scherf U., Liu E.T., Kohn K.W., Pommier Y., Weinstein J.N. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res. 62:2002;1688-1695.
37. Barrows L.R., Holden J.A., Anderson M., D'Arpa P. The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. Mutat. Res. 408:1998;103-110.
38. Plo I., Liao Z.Y., Barceló J.M., Kohlhagen G., Caldecott K.W., Weinfeld M., Pommier Y. Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repairs. 2:2003;1087-1100.
39. Shao R.-G., Cao C.-X., Zhang H., Kohn K.W., Wold M.S., Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J. 18:1999;1397-1406.
40. Snapka R.M. Topoisomerase inhibitors can selectively interfere with different stages of Simian Virus 40 DNA replication. Mol. Cell. Biol. 6:1986;4221-4227.
41. Tsao Y.P., Russo A., Nyamusa G., Silber R., Liu L.F. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res. 53:1993;5908-5914.
42. Strumberg D., Pilon A.A., Smith M., Hickey R., Malkas L., Pommier Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff. Mol. Cell. Biol. 20:2000;3977-3987.
43. Squires S., Ryan A.J., Strutt H.L., Johnson R.T. Hypersensitivity of Cockayne's syndrome cells to camptothecins is associated with the generation of abnormally high levels of double strand breaks in nascent DNA. Cancer Res. 53:1993;2012-2019.
44. Voeller D.M., Grem J.L., Pommier Y., Paull K., Allegra C.J. Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs. Cancer Chemother. Pharmacol. 45:2000;409-416.
45. Wang Y., Ronel Perrault A., Iliakis G. Down-regulation of DNA replication in extracts of camptothecin-treated cells: activation of an S-phase checkpoint? Cancer Res. 57:1997;1654-1659.
46. Kaufmann W.K., Boyer J.C., Estabrooks L.L., Wilson S.J. Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes. Mol. Cell. Biol. 11:1991;3711-3718.
47. Feijoo C., Hall-Jackson C., Wu R., Jenkins D., Leitch J., Gilbert D.M., Smythe C. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J. Cell. Biol. 154:2001;913-923.
48. Dimitrova D.S., Gilbert D.M. Temporally coordinated assembly and disassembly of replication factories in the absence of DNA synthesis. Nat. Cell. Biol. 2:2000;686-694.
49. Shao R.-G., Cao C.-X., Shimizu T., O'Connor P., Kohn K.W., Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53. Cancer Res. 57:1997;4029-4035.
50. Busby E.C., Leistritz D.F., Abraham R.T., Karnitz L.M., Sarkaria J.N. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res. 60:2000;2108-2112.
51. Graves P.R., Yu L., Schwarz J.K., Gales J., Sausville E.A., O'Connor P.M., Piwnica-Worms H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 275:2000;5600-5605.
52. Yu Q., La Rose J.H., Zhang H., Pommier Y. Inhibition of Chk2 activity and radiation-induced p53 elevation by the cell cycle checkpoint abrogator 7-hydroxystaurosporine (UCN-01). Proc. Am. Assoc. Cancer Res. 42:2001;800.
53. Kessel D. Effects of camptothecin on RNA synthesis in leukemia cells. Biochim. Biophys. Acta. 246:1971;225-232.
54. Wu R.S., Kumar A., Warner J.R. Ribosome formation is blocked by camptothecin, a reversible inhibitor of RNA synthesis. Proc. Natl. Acad. Sci. U.S.A. 68:1971;3009-3014.
55. Kann H.E. Jr., Kohn K.W. Effects of deoxyribonucleic acid-reactive drugs on ribonucleic acid synthesis in leukemia L1210 cells. Mol. Pharmacol. 8:1972;551-560.
56. Gilmour D.S., Elgin S.C. Localization of specific topoisomerase I interactions within the transcribed region of active heat shock genes by using the inhibitor camptothecin. Mol. Cell. Biol. 7:1987;141-148.
57. Rowe T.C., Couto E., Kroll D.J. Camptothecin inhibits hsp 70 heat-shock transcription and induces DNA strand breaks in hsp 70 genes in Drosophila. NCI Monogr. 4:1987;49-53.
58. Zhang H., Wang J.C., Liu L.F. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc. Natl. Acad. Sci. U.S.A. 85:1988;1060-1064.
59. Stewart A.F., Herrera R.E., Nordheim A. Rapid induction of c-fos transcription reveals quantitive linkage of RNA polymerase II and DNA topoisomerase I enzyme activities. Cell. 60:1990;141-146.
60. Bendixen C., Thomsen B., Alsner J., Westergaard O. Camptothecin- stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry. 29:1990;5613-5619.
61. Muscarella D.E., Rachlinski M.K., Sotiriadis J., Bloom S.E. Contribution of gene-specific lesions, DNA-replication-associated damage, and subsequent transcriptional inhibition in topoisomerase inhibitor-mediated apoptosis in lymphoma cells. Exp. Cell. Res. 238:1998;155-167.
62. Ljungman M., Hanawalt P.C. The anti-cancer drug camptothecin inhibits elongation but stimulates initiation of RNA polymerase II transcription. Carcinogenesis. 17:1996;31-35.
63. Collins I., Weber A., Levens D. Transcriptional consequences of topoisomerase inhibition. Mol. Cell. Biol. 21:2001;8437-8451.
64. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 65:1996;635-692.
65. Duann P., Sun M., Lin C.T., Zhang H., Liu L.F. Plasmid linking number change induced by topoisomerase I-mediated DNA damage. Nucl. Acids Res. 27:1999;2905-2911.
66. Merino A., Madden K.R., Lane W.S., Champoux J.J., Reinberg D. DNA topoisomerase I is involved in both repression and activation of transcription. Nature. 365:1993;227-232.
67. Kretzschmar M., Meisterernst M., Roeder R.G. Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II. Proc. Natl. Acad. Sci. U.S.A. 90:1993;11508-11512.
68. Shykind B.M., Kim J., Stewart L., Champoux J.J., Sharp P.A. Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription. Genes Dev. 11:1997;397-407.
69. Rossi F., Labourier E., Forne T., Divita G., Derancourt J., Riou J.F., Antoine E., Cathala G., Brunel C., Tazi J. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature. 381:1996;80-82.
70. Rossi E., Labourier E., Gallouzi I.-E., Derancourt J., Allemand E., Divita G., Tazi J. The C-terminal domain but not the tyrosine 723 of human DNA topoisomerase I active site contributes to kinase activity. Nucl. Acids Res. 26:1998;2963-2970.
71. Labourier E., Rossi F., Gallouzi I.-E., Allemand E., Divita G., Tazi J. Interaction between the N-terminal domain of human DNA topoisomerase I and the arginine-serine domain of its substrate determines phosphorylation of SF2/ASF splicing factor. Nucl. Acids Res. 26:1998;2955-2962.
72. Straub T., Grue P., Uhse A., Lisby M., Knudsen B.R., Tange T., Westergaard O., Boege F. The RNA-splicing factor PSF/p54 controls DNA-topoisomerase I activity by a direct interaction. J. Biol. Chem. 273:1998;26261-26264.
73. Tazi J., Rossi F., Labourier E., Gallouzi I., Brunel C., Antoine E. DNA topoisomerase I: customs officer at the border between DNA and RNA worlds? J. Mol. Med. 75:1997;786-800.
74. Pilch B., Allemand E., Facompre M., Bailly C., Riou J.F., Soret J., Tazi J. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res. 61:2001;6876-6884.
75. Nelson W.G., Kastan M.B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14:1994;1815-1823.
76. Kharbanda S., Rubin E., Gunji H., Hinz H., Giovanella B., Pantazis P., Kufe D. Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res. 51:1991;6636-6642.
77. Zhao H., Jin S., Fan F., Fan W., Tong T., Zhan Q. Activation of the transcription factor Oct-1 in response to DNA damage. Cancer Res. 60:2000;6276-6280.
78. Piret B., Piette J. Topoisomerase poisons activate the transcription factor NF-kappa B in ACH-2 and CEM cells. Nucl. Acids Res. 24:1996;4242-4248.
79. Huang T.T., Wuerzberger-Davis S.M., Seufzer B.J., Shumway S.D., Kurama T., Boothman D.A., Miyamoto S. NF-kappa B activation by camptothecin. A linkage between nuclear dna damage and cytoplasmic signaling events. J. Biol. Chem. 275:2000;9501-9509.
80. Pommier Y., Jenkins J., Kohlhagen G., Leteurtre F. DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors. Mutat. Res. 337:1995;135-145.
81. Cheng C., Shuman S. Recombinogenic flap ligation pathway for intrinsic repair of topoisomerase IB-induced double-strand breaks. Mol. Cell. Biol. 20:2000;8059-8068.
82. Pouliot J.J., Yao K.C., Robertson C.A., Nash H.A. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topo I covalent complexes. Science. 286:1999;552-555.
83. Yang S.W., Burgin A.B., Huizenga B.N., Robertson C.A., Yao K.C., Nash H.A. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. Proc. Natl. Acad. Sci. U.S.A. 93:1996;11534-11539.
84. Interthal H., Pouliot J.J., Champoux J.J. The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. Proc. Natl. Acad. Sci. U.S.A. 98:2001;12009-12014.
85. Takashima H., Boerkoel C.F., John J., Saifi G.M., Salih M.A., Armstrong D., Mao Y., Quiocho F.A., Roa B.B., Nakagawa M., Stockton D.W., Lupski J.R. Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat. Genet. 32:2002;267-272.
86. Davies D.R., Interthal H., Champoux J.J., Hol W.G. The crystal structure of human tyrosyl-DNA phosphodiesterase, Tdp1. Structure (Camb.). 10:2002;237-248.
87. Stuckey J.A., Dixon J.E. Crystal structure of a phospholipase D family member. Nat. Struct. Biol. 6:1999;278-284.
88. Davies D.R., Interthal H., Champoux J.J., Hol W.G. Crystal structure of a transition state mimic for tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived peptide. Chem. Biol. 10:2003;139-147.
89. Inamdar K.V., Pouliot J.J., Zhou T., Lees-Miller S.P., Rasouli-Nia A., Povirk L.F. Conversion of phosphoglycolate to phosphate termini on 3′ overhangs of DNA double-strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1. J. Biol. Chem. 277:2002;27162-27168.
90. Debethune L., Kohlhagen G., Grandas A., Pommier Y. Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. Nucl. Acids Res. 30:2002;1198-1204.
91. Pouliot J.J., Robertson C.A., Nash H.A. Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae. Genes Cells. 6:2001;677-687.
92. Beidler D.R., Cheng Y.-C. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol. 47:1995;907-914.
93. Desai S.D., Liu L.F., Vazquez-Abad D., D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J. Biol. Chem. 272:1997;24159-24164.
94. Vance J.R., Wilson T.E. Uncoupling of 3′-phosphatase and 5′-kinase functions in budding yeast. Characterization of Saccharomyces cerevisiae DNA 3'-phosphatase (TPP1). J. Biol. Chem. 276:2001;15073-15081.
95. Liu C., Pouliot J.J., Nash H.A. Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1. Proc. Natl. Acad. Sci. U.S.A. 99:2002;14970-14975.
96. Vance J.R., Wilson T.E. Repair of DNA strand breaks by the overlapping functions of lesion-specific and non-lesion-specific DNA 3′ phosphatases. Mol. Cell. Biol. 21:2001;7191-7198.
97. Meijer M., Karimi-Busheri F., Huang T.Y., Weinfeld M., Young D. Pnk1, a DNA kinase/phosphatase required for normal response to DNA damage by gamma-radiation or camptothecin in Schizosaccharomyces pombe. J. Biol. Chem. 277:2002;4050-4055.
98. Karimi-Busheri F., Daly G., Robins P., Canas B., Pappin D.J.C., Sgouros J., Miller G.G., Fakhrai H., Davis E.M., Le Beau M.M., Weinfeld M. Molecular characterization of a human DNA kinase. J. Biol. Chem. 274:1999;24187-24194.
99. Jilani A., Ramotar D., Slack C., Ong C., Yang X.M., Scherer S.W., Lasko D.D. Molecular cloning of the human gene, PNKP, encoding a polynucleotide kinase 3′-phosphatase and evidence for its role in repair of DNA strand breaks caused by oxidative damage. J. Biol. Chem. 274:1999;24176-24186.
100. Wilson D.M. 3rd Properties of and substrate determinants for the exonuclease activity of human apurinic endonuclease Ape1. J. Mol. Biol. 330:2003;1027-1037.
101. Davies D.R., Interthal H., Champoux J.J., Hol W.G. Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures. J. Mol. Biol. 324:2002;917-932.
102. Vance J.R., Wilson T.E. Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage. Proc. Natl. Acad. Sci. U.S.A. 99:2002;13669-13674.
103. Bastin-Shanower S.A., Fricke W.M., Mullen J.R., Brill S.J. The mechanism of mus81-mms4 cleavage site selection distinguishes it from the homologous endonuclease rad1-rad10. Mol. Cell. Biol. 23:2003;3487-3496.
104. D'Amours D., Jackson S.P. The Mre11 complex: at the crossroads of DNA repair and checkpoint signalling. Nat. Rev. Mol. Cell. Biol. 3:2002;317-327.
105. Doe C.L., Ahn J.S., Dixon J., Whitby M.C. Mus81-Eme1 and Rqh1 involvement in processing stalled and collapsed replication forks. J. Biol. Chem. 277:2002;32753-32759.
106. Ciccia A., Constantinou A., West S.C. Identification and characterization of the human Mus81/Eme1 endonuclease. J. Biol. Chem. 278:2003;25172-25178.
107. Bennett C.B., Lewis L.K., Karthikeyan G., Lobachev K.S., Jin Y.H., Sterling J.F., Snipe J.R., Resnick M.A. Genes required for ionizing radiation resistance in yeast. Nat. Genet. 29:2001;426-434.
108. Whitehouse C.J., Taylor R.M., Thistlethwaite A., Zhang H., Karimi-Busheri F., Lasko D.D., Weinfeld M., Caldecott K.W. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand breaks. Cell. 104:2001;107-117.
109. Thompson L.H., West M.G. XRCC1 keeps DNA from getting stranded. Mutat. Res. 459:2000;1-18.
110. Vidal A.E., Boiteux S., Hickson I.D., Radicella J.P. XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J. 20:2001;6530-6539.
111. de Murcia G., Ménissier de Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. TIBS. 19:1994;172-176.
112. D'Amours D., Desnoyers S., D'Silva I., Poirier G.G. Poly(ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem. J. 342:1999;249-268.
113. de Murcia G., Menissier de Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem. Sci. 19:1994;172-176.
114. Kasid U.N., Halligan B., Liu L.F., Dritschilo A., Smulson M. Poly(ADP-ribose)-mediated post-translational modification of chromatin-associated human topoisomerase I. Inhibitory effects on catalytic activity. J. Biol. Chem. 264:1989;18687-18692.
115. Ferro A.M., Olivera B.M. Poly(ADP-ribosylation) of DNA topoisomerase I from calf thymus. J. Biol. Chem. 259:1984;547-554.
116. Smith H.M., Grosovsky A.J. PolyADP-ribose-mediated regulation of p53 complexed with topoisomerase I following ionizing radiation. Carcinogenesis. 20:1999;1439-1444.
117. Bauer P.I., Buki K.G., Comstock J.A., Kun E. Activation of topoisomerase I by poly [ADP-ribose] polymerase. Int. J. Mol. Med. 5:2000;533-540.
118. Simbulan-Rosenthal C.M., Rosenthal D.S., Iyer S., Boulares A.H., Smulson M.E. Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis. J. Biol. Chem. 273:1998;13703-13712.
119. Chatterjee S., Cheng M.-F., Trivedi D., Petzold S.J., Berger N.A. Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines. Cancer Commun. 1:1989;389-394.
120. Chatterjee S., Hirschler N.V., Petzold S.J., Berger S.J., Berger N.A. Mutant cells defective in poly(ADP-ribose) synthesis due to stable alterations in enzyme activity or substrate availability. Exp. Cell. Res. 184:1989;1-15.
121. Mattern M.R., Mong S.M., Bartus H.F., Mirabelli C.K., Crooke S.T., Johnson R.K. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res. 47:1987;1793-1798.
122. Bowman K.J., Newell D.R., Calvert A.H., Curtin N.J. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br. J. Cancer. 84:2001;106-112.
123. Staron K., Kowalska-Loth B., Nieznanski K., Szumiel I. Phosphorylation of topoisomerase I in L5178Y-S cells is associated with poly(ADP-ribose) metabolism. Carcinogenesis. 17:1996;383-387.
124. Caldecott K., Jeggo P. Cross-sensitivity of gamma-ray-sensitive hamster mutants to cross-linking agents. Mutat. Res. 255:1991;111-121.
125. Park S.Y., Lam W., Cheng Y.C. X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res. 62:2002;459-465.
126. Haber J.E. Lucky breaks: analysis of recombination in Saccharomyces. Mutat. Res. 451:2000;53-69.
127. Kraus E., Leung W.Y., Haber J.E. Break-induced replication: a review and an example in budding yeast. Proc. Natl. Acad. Sci. U.S.A. 98:2001;8255-8262.
128. Arnaudeau C., Tenorio Miranda E., Jenssen D., Helleday T. Inhibition of DNA synthesis is a potent mechanism by which cytostatic drugs induce homologous recombination in mammalian cells. Mutat. Res. 461:2000;221-228.
129. Michel B., Flores M.J., Viguera E., Grompone G., Seigneur M., Bidnenko V. Rescue of arrested replication forks by homologous recombination. Proc. Natl. Acad. Sci. U.S.A. 98:2001;8181-8188.
130. Klein H.L., Kreuzer K.N. Replication, recombination, and repair: going for the gold. Mol. Cell. 9:2002;471-480.
131. Baumann P., West S.C. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem. Sci. 23:1998;247-251.
132. D'Andrea A.D., Grompe M. The Fanconi Anaemia/BRCA pathway. Nat. Rev. Cancer. 3:2003;23-34.
133. Meetei A.R., Sechi S., Wallisch M., Yang D., Young M.K., Joenje H., Hoatlin M.E., Wang W. A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol. Cell. Biol. 23:2003;3417-3426.
134. West S.C. Molecular views of recombination proteins and their control. Nat. Rev. Mol. Cell. Biol. 4:2003;435-445.
135. Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q., De Die-Smulders C., Persky N., Grompe M., Joenje H., Pals G., Ikeda H., Fox E.A., D'Andrea A.D. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 297:2002;606-609.
136. Pellegrini L., Yu D.S., Lo T., Anand S., Lee M., Blundell T.L., Venkitaraman A.R. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature. 420:2002;287-293.
137. Yang H., Jeffrey P.D., Miller J., Kinnucan E., Sun Y., Thoma N.H., Zheng N., Chen P.L., Lee W.H., Pavletich N.P. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science. 297:2002;1837-1848.
138. Postow L., Ullsperger C., Keller R.W., Bustamante C., Vologodskii A.V., Cozzarelli N.R. Positive torsional strain causes the formation of a four-way junction at replication forks. J. Biol. Chem. 276:2001;2790-2796.
139. Gaymes T.J., North P.S., Brady N., Hickson I.D., Mufti G.J., Rassool F.V. Increased error-prone non homologous DNA end-joining - a proposed mechanism of chromosomal instability in Bloom's syndrome. Oncogene. 21:2002;2525-2533.
140. Sordet O., Khan Q., Kohn K.W., Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anticancer Agents. 3:2003;271-290.
141. Rubin E., Wood V., Bharti A., Trites D., Lynch C., Hurwitz S., Bartel S., Levy S., Rosowsky A., Toppmeyer D. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin. Cancer Res. 1:1995;269-276.
142. Desai S.D., Li T.K., Rodriguez-Bauman A., Rubin E.H., Liu L.F. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 61:2001;5926-5932.
143. Desai S.D., Zhang H., Rodriguez-Bauman A., Yang J.M., Wu X., Gounder M.K., Rubin E.H., Liu L.F. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol. Cell. Biol. 23:2003;2341-2350.
144. Fu Q., Kim S.W., Chen H.X., Grill S., Cheng Y.C. Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death. Mol. Pharmacol. 55:1999;677-683.
145. Saleem A., Edwards T.K., Rasheed Z., Rubin E.H. Mechanisms of resistance to camptothecins. Ann. N. Y. Acad. Sci. 922:2000;46-55.
146. Mao Y., Sun M., Desai S.D., Liu L.F. SUMO-1 conjugation to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage. Proc. Natl. Acad. Sci. U.S.A. 97:2000;4046-4051.
147. D'Arpa P., Liu L.F. Cell cycle-specific and transcription-related phosphorylation of mammalian topoisomerase I. Exp. Cell. Res. 217:1995;125-131.
148. Horie K., Tomida A., Sugimoto Y., Yasugi T., Yoshikawa H., Taketani Y., Tsuruo T. SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin. Oncogene. 21:2002;7913-7922.
149. Cusack J.C. Jr., Liu R., Houston M., Abendroth K., Elliott P.J., Adams J., Baldwin A.S. Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappa B inhibition. Cancer Res. 61:2001;3535-3540.
150. Mao Y., Sun M., Desai S.D., Liu L.F. SUMO-1 conjugation to topoisomerase I: a possible repair response to topoisomerase-mediated DNA damage. Proc. Natl. Acad. Sci. U.S.A. 97:2000;4046-4051.
151. Mo Y.-Y., Yu Y., Shen Z., Beck W.T. Nucleolar delocalization of human topoisomerase i in response to topotecan correlates with sumoylation of the protein. J. Biol. Chem. 277:2002;2958-2964.
152. Verger A., Perdomo J., Crossley M. Modification with SUMO. A role in transcriptional regulation. EMBO Rep. 4:2003;137-142.
153. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer. 3:2003;155-168.
154. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 421:2003;499-506.
155. Smith P.J., Makinson T.A., Watson J.V. Enhanced sensitivity to camptothecin in ataxia telangiectasia cells and its relationship with the expression of DNA topoisomerase I. Int. J. Radiat. Biol. 55:1989;217-231.
156. Johnson M.A., Jones N.J. The isolation and genetic analysis of V79-derived etoposide sensitive Chinese hamster cell mutants: two new complementation groups of etoposide sensitive mutants. Mutat. Res. 435:1999;271-282.
157. Jones N.J., Ellard S., Waters R., Parry E.M. Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's Anaemia cells. Carcinogenesis. 14:1993;2487-2494.
158. Johnson M.A., Bryant P.E., Jones N.J. Isolation of camptothecin- sensitive Chinese hamster cell mutants: phenotypic heterogeneity within the ataxia telangiectasia-like XRCC8 (irs2) complementation group. Mutagenesis. 15:2000;367-374.
159. Banin S., Moyal L., Shieh S.-Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281:1998;1674-1677.
160. Canman C.E., Lim D.S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M.B., Siliciano J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 281:1998;1677-1679.
161. Khanna K.K., Keating K.E., Kozlov S., Scott S., Gatei M., Hobson K., Taya Y., Gabrielli B., Chan D., Lees-Miller S.P., Lavin M.F. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat. Genet. 20:1998;398-400.
162. Matsuoka S., Huang M., Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science. 282:1998;893-897.
163. Lim D.S., Kim S.T., Xu B., Maser R.S., Lin J., Petrini J.H., Kastan M.B. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature. 404:2000;613-617.
164. Zhao S., Weng Y.C., Yuan S.S., Lin Y.T., Hsu H.C., Lin S.C., Gerbino E., Song M.H., Zdzienicka M.Z., Gatti R.A., Shay J.W., Ziv Y., Shiloh Y., Lee E.Y. Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products. Nature. 405:2000;473-477.
165. Gatei M., Young D., Cerosaletti K.M., Desai-Mehta A., Spring K., Kozlov S., Lavin M.F., Gatti R.A., Concannon P., Khanna K. ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat. Genet. 25:2000;115-119.
166. Wu X., Ranganathan V., Weisman D.S., Heine W.F., Ciccone D.N., O'Neill T.B., Crick K.E., Pierce K.A., Lane W.S., Rathbun G., Livingston D.M., Weaver D.T. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature. 405:2000;477-482.
167. Cortez D., Wang Y., Qin J., Elledge S.J. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science. 286:1999;1162-1166.
168. Rappold I., Iwabuchi K., Date T., Chen J. Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J. Cell. Biol.
169. Redon C., Pilch D., Rogakou E., Sedelnikova O., Newrock K., Bonner W. Histone H2A variants H2AX and H2AZ. Curr. Opin. Genet. Dev. 12:2002;162-169.
170. Wu X., Petrini J.H., Heine W.F., Weaver D.T., Livingston D.M., Chen J. Independence of R/M/N focus formation and the presence of intact BRCA1a. Science. 289:2000;11.
171. Xu B., Kim S., Kastan M.B. Involvement of Brca1 in S-phase and G(2) -phase checkpoints after ionizing irradiation. Mol. Cell. Biol. 21:2001;3445-3450.
172. Piret B., Schoonbroodt S., Piette J. The ATM protein is required for sustained activation of NF-kappa B following DNA damage. Oncogene. 18:1999;2261-2271.
173. Furuta T., Takemura H., Liao Z.Y., Aune G.J., Redon C., Sedelnikova O.A., Pilch D.R., Rogakou E.P., Celeste A., Chen H.T., Nussenzweig A., Aladjem M.I., Bonner W.M., Pommier Y. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA-double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem. 278:2003;20303-20312.
174. Petrini J.H. The Mre11 complex and ATM: collaborating to navigate S phase. Curr. Opin. Cell. Biol. 12:2000;293-296.
175. Hopfner K.P., Putnam C.D., Tainer J.A. DNA double-strand break repair from head to tail. Curr. Opin. Struct. Biol. 12:2002;115-122.
176. Zhong Q., Chen C.F., Li S., Chen Y., Wang C.C., Xiao J., Chen P.L., Sharp Z.D., Lee W.H. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science. 285:1999;747-750.
177. Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 14:2000;927-939.
178. Paull T.T., Gellert M. The 3′ to 5′ exonuclease activity of Mre11 facilitates repair of DNA double-strand breaks. Mol. Cell. 1:1998;969-979.
179. Paull T.T., Rogakou E.P., Yamazaki V., Kirchgessner C.U., Gellert M., Bonner W.M. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol. 10:2000;886-895.
180. Stewart G.S., Maser R.S., Stankovic T., Bressan D.A., Kaplan M.I., Jaspers N.G., Raams A., Byrd P.J., Petrini J.H., Taylor A.M. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell. 99:1999;577-587.
181. Mirzoeva O.K., Petrini J.H. DNA damage-dependent nuclear dynamics of the mre11 complex. Mol. Cell. Biol. 21:2001;281-288.
182. Gatei M., Sloper K., Sorensen C., Syljuasen R., Falck J., Hobson K., Savage K., Lukas J., Zhou B.B., Bartek J., ATM and NBS1 dependent phosphorylation of CHK1 on S317 in response to IR K.K.Khanna. J. Biol. Chem. 278:2003;14806-14811.
183. Paull T.T., Gellert M. A mechanistic basis for Mre11-directed DNA joining at microhomologies. Proc. Natl. Acad. Sci. U.S.A. 97:2000;6409-6414.
184. Dong Z., Zhong Q., Chen P.L. The Nijmegen breakage syndrome protein is essential for Mre11 phosphorylation upon DNA damage. J. Biol. Chem. 274:1999;19513-19516.
185. Kraakman-van der Zwet M., Overkamp W.J., Friedl A.A., Klein B., Verhaegh G.W., Jaspers N.G., Midro A.T., Eckardt-Schupp F., Lohman P.H., Zdzienicka M.Z. Immortalization and characterization of Nijmegen breakage syndrome fibroblasts. Mutat. Res. 434:1999;17-27.
186. Wu J., Yin M.B., Hapke G., Toth K., Rustum Y.M. Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin. Mol. Pharmacol. 61:2002;742-748.
187. Redon C., Pilch D., Rogakou E., Orr A.H., Lowndes N.F., Bonner W.M. Yeast histone 2A serine 129 is essential for the efficient repair of checkpoint-blind DNA damage. EMBO Rep. 4:2003;1-7.
188. Simon J.A., Szankasi P., Nguyen D.K., Ludlow C., Dunstan H.M., Roberts C.J., Jensen E.L., Hartwell L.H., Friend S.H. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res. 60:2000;328-333.
189. Culmsee C., Bondada S., Mattson M.P. Hippocampal neurons of mice deficient in DNA-dependent protein kinase exhibit increased vulnerability to DNA damage, oxidative stress and excitotoxicity. Brain Res. Mol. Brain Res. 87:2001;257-262.
190. Kharbanda S., Pandey P., Jin S., Inoue S., Yuan Z.-M., Weichselbaum R., Weaver D., Kufe D. Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature. 386:1997;732-735.
191. Zou L., Elledge S.J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science. 300:2003;1542-1548.
192. Costanzo V., Shechter D., Lupardus P.J., Cimprich K.A., Gottesman M., Gautier J. An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication. Mol. Cell. 11:2003;203-213.
193. Caspari T., Carr A.M. Checkpoints: how to flag up double-strand breaks. Curr. Biol. 12:2002;R105-107.
194. Brown E.J., Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14:2000;397-402.
195. Brown E.J., Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev. 17:2003;615-628.
196. O'Driscoll M., Ruiz-Perez V.L., Woods C.G., Jeggo P.A., Goodship J.A. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat. Genet. 33:2003;497-501.
197. Cortez D., Guntuku S., Qin J., Elledge S.J. ATR and ATRIP: partners in checkpoint signaling. Science. 294:2001;1713-1716.
198. Xiao Z., Chen Z., Gunasekera A.H., Sowin T.J., Rosenberg S.H., Fesik S., Zhang H. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J. Biol. Chem. 278:2003;21767-21773.
199. Cliby W.A., Roberts C.J., Cimprich K.A., Stringer C.M., Lamb J.R., Schreiber S.L., Friend S.H. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J. 17:1998;159-169.
200. Cliby W.A., Lewis K.A., Lilly K.K., Kaufmann S.H. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J. Biol. Chem. 277:2002;1599-1606.
201. Walworth N., Bernards R. Rad-dependent responses of the Chk1-encoded protein kinase at the DNA damage checkpoint. Science. 271:1996;353-356.
202. Walworth N.C. Rad9 comes of age. Science. 281:1998;185-186.
203. Brondello J.M., Boddy M.N., Furnari B., Russell P. Basis for the checkpoint signal specificity that regulates chk1 and cds1 protein kinases. Mol. Cell. Biol. 19:1999;4262-4269.
204. Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature. 408:2000;433-439.
205. Zhang H., Siede W. Validation of a novel assay for checkpoint responses: characterization of camptothecin derivatives in Saccharomyces cerevisiae. Mutat. Res. 527:2003;37-48.
206. Caspari T., Dahlen M., Kanter-Smoler G., Lindsay H.D., Hofmann K., Papadimitriou K., Sunnerhagen P., Carr A.M. Characterization of Schizosaccharomyces pombe Hus1: a PCNA-related protein that associates with Rad1 and Rad9. Mol. Cell. Biol. 20:2000;1254-1262.
207. Kondo T., Matsumoto K., Sugimoto K. Role of a complex containing rad17, mec3, and ddc1 in the yeast DNA damage checkpoint pathway. Mol. Cell. Biol. 19:1999;1136-1143.
208. Kostrub C.F., al-Khodairy F., Ghazizadeh H., Carr A.M., Enoch T. Molecular analysis of hus1+, a fission yeast gene required for S-M and DNA damage checkpoints. Mol. Gen. Genet. 254:1997;389-399.
209. Burtelow M.A., Roos-Mattjus P.M., Rauen M., Babendure J.R., Karnitz L.M. Reconstitution and molecular analysis of the hRad9-hHus1-hRad1 (9-1-1) DNA damage responsive checkpoint complex. J. Biol. Chem. 276:2001;25903-25909.
210. Volkmer E., Karnitz L.M. Human homologs of Schizosaccharomyces pombe rad1, hus1, and rad9 form a DNA damage-responsive protein complex. J. Biol. Chem. 274:1999;567-570.
211. Rauen M., Burtelow M.A., Dufault V.M., Karnitz L.M. The human checkpoint protein hRad17 interacts with the PCNA-like proteins hRad1, hHus1, and hRad9. J. Biol. Chem. 275:2000;29767-29771.
212. Dahm K., Hubscher U. Colocalization of human Rad17 and PCNA in late S phase of the cell cycle upon replication block. Oncogene. 21:2002;7710-7719.
213. Venclovas C., Thelen M.P. Structure-based predictions of Rad1, Rad9, Hus1 and Rad17 participation in sliding clamp and clamp-loading complexes. Nucl. Acids Res. 28:2000;2481-2493.
214. Bermudez V.P., Lindsey-Boltz L.A., Cesare A.J., Maniwa Y., Griffith J.D., Hurwitz J., Sancar A. Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro. Proc. Natl. Acad. Sci. U.S.A. 100:2003;1633-1638.
215. Kai M., Wang T.S. Checkpoint activation regulates mutagenic translesion synthesis. Genes Dev. 17:2003;64-76.
216. Wang X., Zou L., Zheng H., Wei Q., Elledge S.J., Li L. Genomic instability and endoreduplication triggered by RAD17 deletion. Genes Dev. 17:2003;965-970.
217. Burtelow M.A., Kaufmann S.H., Karnitz L.M. Retention of the human Rad9 checkpoint complex in extraction-resistant nuclear complexes after DNA damage. J. Biol. Chem. 275:2000;26343-26348.
218. Weiss R.S., Enoch T., Leder P. Inactivation of mouse Hus1 results in genomic instability and impaired responses to genotoxic stress. Genes Dev. 14:2000;1886-1898.
219. Chakraverty R.K., Kearsey J.M., Oakley T.J., Grenon M., de La Torre Ruiz M.A., Lowndes N.F., Hickson I.D. Topoisomerase III acts upstream of Rad53p in the S-phase DNA damage checkpoint. Mol. Cell. Biol. 21:2001;7150-7162.
220. Goodwin A., Wang S.W., Toda T., Norbury C., Hickson I.D. Topoisomerase III is essential for accurate nuclear division in Schizosaccharomyces pombe. Nucl. Acids Res. 27:1999;4050-4058.
221. Gangloff S., de Massy B., Arthur L., Rothstein R., Fabre F. The essential role of yeast topoisomerase III in meiosis depends on recombination. EMBO J. 18:1999;1701-1711.
222. Liao S., Graham J., Yan H. The function of xenopus Bloom's syndrome protein homolog (xBLM) in DNA replication. Genes Dev. 14:2000;2570-2575.
223. Yankiwski V., Marciniak R.A., Guarente L., Neff N.F. Nuclear structure in normal and Bloom syndrome cells. Proc. Natl. Acad. Sci. U.S.A. 97:2000;5214-5219.
224. Kamath-Loeb A.S., Johansson E., Burgers P.M., Loeb L.A. Functional interaction between the werner syndrome protein and DNA polymerase delta. Proc. Natl. Acad. Sci. U.S.A. 97:2000;4603-4608.
225. Rothstein R., Michel B., Gangloff S. Replication fork pausing and recombination or "gimme a break" Genes Dev. 14:2000;1-10.
226. Watt P.M., Louis E.J., Borts R.H., Hickson I.D. Sgs1: a eukaryotic homolog of E. coli RecQ that interacts with topoisomerase II in vivo and is required for faithful chromosome segregation. Cell. 81:1995;253-260.
227. Gangloff S., MacDonald J.P., Bendixen C., Arthur L., Rothstein R. The yeast type 1 topoisomerase Top3 interacts with Sgs1, a DNA helicase homolog: a potential eukaryotic reverse gyrase. Mol. Cell. Biol. 14:1994;8391-8398.
228. Lu J., Mullen J.R., Brill S.J., Kleff S., Romeo A.M., Sternglanz R. Human homologues of yeast helicase. Nature. 383:1996;678-679.
229. Hickson I.D. RecQ helicases: caretakers of the genome. Nat. Rev. Cancer. 3:2003;169-178.
230. Yamagata K., Kato J., Shimamoto A., Goto M., Furuichi Y., Ikeda H. Bloom's and Werner's syndrome genes suppress hyperrecombination in yeast Sgs1 mutant: implication for genomic instability in human diseases. Proc. Natl. Acad. Sci. U.S.A. 95:1998;8733-8738.
231. Lebel M., Leder P. A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of proliferative capacity. Proc. Natl. Acad. Sci. U.S.A. 95:1998;13097-13102.
232. Poot M., Gollahon K.A., Rabinovitch P.S. Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum. Genet. 104:1999;10-14.
233. Pichierri P., Franchitto A., Mosesso P., Palitti F. Werner's syndrome cell lines are hypersensitive to camptothecin-induced chromosomal damage. Mutat. Res. 456:2000;45-57.
234. Imamura O., Fujita K., Itoh C., Takeda S., Furuichi Y., Matsumoto T. Werner and Bloom helicases are involved in DNA repair in a complementary fashion. Oncogene. 21:2002;954-963.
235. Sakamoto S., Nishikawa K., Heo S.J., Goto M., Furuichi Y., Shimamoto A. Werner helicase relocates into nuclear foci in response to DNA damaging agents and co-localizes with RPA and Rad51. Genes Cells. 6:2001;421-430.
236. Li B., Comai L. Functional interaction between Ku and the werner syndrome protein in DNA end processing. J. Biol. Chem. 275:2000;39800.
237. Brosh R.M. Jr., Bohr V.A. Roles of the Werner syndrome protein in pathways required for maintenance of genome stability. Exp. Gerontol. 37:2002;491-506.
238. Franchitto A., Pichierri P. Bloom's syndrome protein is required for correct relocalization of RAD50/MRE11/NBS1 complex after replication fork arrest. J. Cell. Biol. 157:2002;19-30.
239. Ababou M., Dumaire V., Lecluse Y., Amor-Gueret M. Bloom's syndrome protein response to ultraviolet-C radiation and hydroxyurea-mediated DNA synthesis inhibition. Oncogene. 21:2002;2079-2088.
240. Beamish H., Kedar P., Kaneko H., Chen P., Fukao T., Peng C., Beresten S., Gueven N., Purdie D., Lees-Miller S., Ellis N., Kondo N., Lavin M.F. Functional link between BLM defective in Bloom's syndrome and the ataxia-telangiectasia-mutated protein, ATM. J. Biol. Chem. 277:2002;30515-30523.
241. Slichenmyer W.J., Nelson W.G., Slebos R.J., Kastan M.B. Loss of a p53-associated G1 checkpoint does not increase cell survival following DNA damage. Cancer Res. 53:1993;4164-4168.
242. Gupta M., Fan S., Zhan Q., Kohn K.W., O'Connor P.M., Pommier Y. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin. Cancer Res. 3:1997;1653-1660.
243. Canman C.E., Wolff A.C., Chen C.-H., Fornace A.J., Kastan M.B. The p53-dependent cell cycle checkpoint pathway and ataxia-telangiectansia. Cancer Res. 54:1994;5054-5058.
244. Fedier A., Steiner R.A., Schwarz V.A., Lenherr L., Haller U., Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22:2003;1169-1173.
245. Rahden-Staron I.I., Szumilo M., Grosicka E., Kraakman Van Der Zwet M., Zdzienicka M.Z. Defective Brca2 influences topoisomerase I activity in mammalian cells. Acta Biochim. Pol. 50:2003;139-144.
246. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C., Hejna J., Grompe M., D'Andrea A.D. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell. 7:2001;249-262.
247. Saito H., Grompe M., Neeley T.L., Jakobs P.M., Moses R.E. Fanconi anemia cells have a normal gene structure for topoisomerase I. Hum. Genet. 93:1994;583-586.
248. Poot M., Hoehn H. DNA topoisomerases and the DNA lesion in human genetic instability syndromes. Toxicol. Lett. 67:1993;297-308.
249. Rosselli F., Duchaud E., Averbeck D., Moustacchi E. Comparison of the effects of DNA topoisomerase inhibitors on lymphoblasts from normal and Fanconi anemia donors. Mutat. Res. 325:1994;137-144.
250. Taniguchi T., Dandrea A.D. Molecular pathogenesis of Fanconi anemia. Int. J. Hematol. 75:2002;123-128.
251. Sun M., Duann P., Lin C.T., Zhang H., Liu L.F. Rapid chromatin reorganization induced by topoisomerase I-mediated DNA damage. Ann. N. Y. Acad. Sci. 922:2000;340-342.
252. Citterio E., Van Den Boom V., Schnitzler G., Kanaar R., Bonte E., Kingston R.E., Hoeijmakers J.H., Vermeulen W. ATP-Dependent chromatin remodeling by the Cockayne syndrome B DNA repair-transcription-coupling factor. Mol. Cell. Biol. 20:2000;7643-7653.
253. Walowsky C., Fitzhugh D.J., Castaño I.B., Ju J.Y., Levin N.A., Christman M.F. The topoisomerase-related function gene TRF4 affects cellular sensitivity to the antitumor agent camptothecin. J. Biol. Chem. 274:1999;7302-7308.
254. Choy J.S., Kron S.J. NuA4 subunit Yng2 function in intra-S-phase DNA damage response. Mol. Cell. Biol. 22:2002;8215-8225.
255. Bird A.W., Yu D.Y., Pray-Grant M.G., Qiu Q., Harmon K.E., Megee P.C., Grant P.A., Smith M.M., Christman M.F. Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair. Nature. 419:2002;411-415.
256. Arnaudeau C., Lundin C., Helleday T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J. Mol. Biol. 307:2001;1235-1245.
257. Andersen F.F., Andersen K.E., Kusk M., Frohlich R.F., Westergaard O., Andersen A.H., Knudsen B.R. Recombinogenic flap ligation mediated by human topoisomerase I. J. Mol. Biol. 330:2003;235-246.
258. Christiansen K., Knudsen B.R., Westergaard O. The covalent eukaryotic topoisomerase I-DNA intermediate catalyzes pH-dependent hydrolysis and alcoholysis. J. Biol. Chem. 269:1994;11367-11373.
259. Krogh B.O., Shuman S. DNA strand transfer catalyzed by vaccinia topoisomerase: peroxidolysis and hydroxylaminolysis of the covalent protein-DNA intermediate. Biochemistry. 39:2000;6422-6432.
260. Arimondo P.B., Boutorine A., Baldeyrou B., Bailly C., Kuwahara M., Hecht S.M., Sun J.-S., Garestier T., Helene C. Design and optimization of camptothecin conjugates of triple helix-forming oligonucleotides for sequence-specific DNA cleavage by topoisomerase I. J. Biol. Chem. 277:2002;3132-3140.
261. Pourquier P., Takebayashi Y., Urasaki Y., Gioffre C., Kohlhagen G., Pommier Y. Induction of topoisomerase I cleavage complexes by 1-b-D-arabinofuranosylcytosine (Ara-C) in vitro and in ara-C-treated cells. Proc. Natl. Acad. Sci. U.S.A. 97:2000;1885-1890.
262. Chrencik J.E., Burgin A.B., Pommier Y., Stewart L., Redinbo M.R. Structural impact of the leukemia drug Ara-C on the covalent human topoisomerase I DNA complex. J. Biol. Chem. 278:2003;12461-12466.
263. Pourquier P., Ueng L.-M., Kohlhagen G., Mazumder A., Gupta M., Kohn K.W., Pommier Y. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J. Biol. Chem. 272:1997;7792-7796.
264. Leteurtre F., Kohlhagen G., Fesen M.R., Tanizawa A., Kohn K.W., Pommier Y. Effects of DNA methylation on topoisomerase I and II cleavage activities. J. Biol. Chem. 269:1994;7893-7900.
265. Lanza A., Tornatelli S., Rodolfo C., Scanavini M.C., Pedrini A.M. Human DNA topoisomerase I-mediated cleavages stimulated by ultraviolet light-induced DNA damage. J. Biol. Chem. 271:1996;6978-6986.
266. Subramanian D., Rosenstein B.S., Muller M.T. Ultraviolet-induced DNA damage stimulates topoisomerase I-DNA complex formation in vivo: possible relationship with DNA repair. Cancer Res. 58:1998;976-984.
267. 6-methylguanine. Cancer Res. 61:2001;53-58.
268. Pommier Y., Kohlhagen G., Laco G.S., Sayer J.M., Kroth H., Jerina D.M. Position-specific trapping of topoisomerase I-DNA cleavage complexes by the intercalated benzo[a]pyrene diol epoxide adducts at the 6-amino group of adenine. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10739-10744.
269. Pommier Y., Kohlhagen G., Pourquier P., Sayer J.M., Kroth H., Jerina D.M. Benzo[a]pyrene epoxide adducts in DNA are potent inhibitors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages. Proc. Natl. Acad. Sci. U.S.A. 97:2000;2040-2045.
270. Pourquier P., Bjornsti M.-A., Pommier Y. Induction of topoisomerase I cleavage complexes by the vinyl chloride adduct, 1,N-6-ethenoadenine. J. Biol. Chem. 273:1998;27245-27249.
271. Johnson R.T., Gotoh E., Mullinger A.M., Ryan A.J., Shiloh Y., Ziv Y., Squires S. Targeting double-strand breaks to replicating DNA identifies a subpathway of DSB repair that is defective in ataxia-telangiectasia cells. Biochem. Biophys. Res. Commun. 261:1999;317-325.
272. Hinz J.M., Helleday T., Meuth M. Reduced apoptotic response to camptothecin in CHO cells deficient in XRCC3. Carcinogenesis. 24:2003;249-253.
273. Thacker J., Ganesh A.N. DNA-break repair, radioresistance of DNA synthesis, and camptothecin sensitivity in the radiation-sensitive irs mutants: comparisons to ataxia-telangiectasia cells. Mutat. Res. 235:1990;49-58.
274. Godthelp B.C., Wiegant W.W., van Duijn-Goedhart A., Scharer O.D., van Buul P.P., Kanaar R., Zdzienicka M.Z. Mammalian Rad51C contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability. Nucl. Acids Res. 30:2002;2172-2182.
275. Chatterjee S., Cheng M.F., Berger N.A. Hypersensitivity to clinically useful alkylating agents and radiations in poly(ADP-ribose) polymerase- deficient cell lines. Cancer Commun. 2:1990;401-407.
276. Han Z., Wei W., Dunaway S., Darnowski J.W., Calabresi P., Sedivy J., Hendrickson E.A., Balan K.V., Pantazis P., Wyche J.H. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem. 277:2002;17154-17160.
277. Walton M.I., Whysong D., O'Connor P.M., Hockenbery D., Korsmeyer S.J., Kohn K.W. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 53:1993;1853-1861.
278. Nitiss J., Wang J.C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. U.S.A. 85:1988;7501-7505.
279. Eng W.K., Faucette L., Johnson R.K., Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol. 34:1988;755-760.
280. Hryciw T., Tang M., Fontanie T., Xiao W. MMS1 protects against replication-dependent DNA damage in Saccharomyces cerevisiae. Mol. Genet. Genom. 266:2002;848-857.
281. Reid R.J., Fiorani P., Sugawara M., Bjornsti M.A. CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage. Proc. Natl. Acad. Sci. U.S.A. 96:1999;11440-11445.
282. Scheller J., Schurer A., Rudolph C., Hettwer S., Kramer W. MPH1, a yeast gene encoding a DEAH protein, plays a role in protection of the genome from spontaneous and chemically induced damage. Genetics. 155:2000;1069-1081.
283. Fiorani P., Bjornsti M.A. Mechanisms of DNA topoisomerase I-induced cell killing in the yeast Saccharomyces cerevisiae. Ann. N. Y. Acad. Sci. 922:2000;65-75.
284. Wan S., Capasso H., Walworth N.C. The topoisomerase I poison camptothecin generates a Chk1-dependent DNA damage checkpoint signal in fission yeast. Yeast. 15:1999;821-828.
285. Francesconi S., Smeets M., Grenon M., Tillit J., Blaisonneau J., Baldacci G. Fission yeast chk1 mutants show distinct responses to different types of DNA damaging treatments. Genes Cells. 7:2002;663-673.
286. Dalgaard J.Z., Klar A.J. swi1 and swi3 perform imprinting, pausing, and termination of DNA replication in S. pombe. Cell. 102:2000;745-751.